Published in Adv Drug Deliv Rev on March 21, 2016
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection | NCT01734850
Gene Therapy: A Paradigm Shift in Dentistry. Genes (Basel) (2016) 0.75
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant? Front Immunol (2017) 0.75
Vaccine nanoparticles for protection against HIV infection. Nanomedicine (Lond) (2017) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Mechanisms of gene silencing by double-stranded RNA. Nature (2004) 16.82
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88
Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell (2006) 11.98
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell (2005) 9.35
Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol (2008) 8.96
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 7.06
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Cas9 as a versatile tool for engineering biology. Nat Methods (2013) 6.87
Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell (2005) 6.47
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 6.37
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature (2005) 6.23
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science (2010) 5.84
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res (2004) 5.46
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 4.85
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature (2010) 3.77
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Argonaute proteins: functional insights and emerging roles. Nat Rev Genet (2013) 3.09
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
The Argonaute protein family. Genome Biol (2008) 2.83
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A (2010) 2.67
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia (2008) 2.66
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther (2008) 2.66
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics (2006) 2.46
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A (2007) 2.30
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A (2010) 2.24
Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet (2015) 2.21
A status report on RNAi therapeutics. Silence (2010) 2.18
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
Expanding the Biologist's Toolkit with CRISPR-Cas9. Mol Cell (2015) 2.11
DEQOR: a web-based tool for the design and quality control of siRNAs. Nucleic Acids Res (2004) 1.97
Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol (2008) 1.97
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest (2011) 1.92
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol (2005) 1.90
CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet (2014) 1.74
Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics (2006) 1.69
HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev (2007) 1.66
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol (2006) 1.60
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol (2015) 1.53
Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res (2007) 1.53
Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol (2008) 1.50
Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One (2009) 1.46
Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev (2006) 1.46
Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov (2003) 1.42
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One (2011) 1.41
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
Potent RNAi by short RNA triggers. RNA (2008) 1.29
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
The prospect of silencing disease using RNA interference. JAMA (2005) 1.24
Engineering nucleases for gene targeting: safety and regulatory considerations. N Biotechnol (2013) 1.24
Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates. Cell Cycle (2010) 1.21
Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther (2009) 1.19
Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet (2015) 1.19
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Absence of DICER in monocytes and its regulation by HIV-1. J Biol Chem (2010) 1.15
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12
Lower and upper stem-single-stranded RNA junctions together determine the Drosha cleavage site. Proc Natl Acad Sci U S A (2013) 1.12
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol (2012) 1.09
Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol (2010) 1.07
Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. Gene Ther (2015) 1.02
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
Lentiviral vector gene therapy: effective and safe? Mol Ther (2010) 0.99
CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Res Ther (2010) 0.99